SIX-MONTH REPORT JANUARY

April–June

  · Net sales rose by about 39% to SEK 3,526k (2,530k).

  · Loss after financial items was SEK 5,287k (loss: 4,803k).

  · Comprehensive income was a loss of SEK 5,348 (loss: 4,803k).

  · Comprehensive income per share basic and diluted totaled SEK -0.22 (-0.22).

  · Cash flow from operating activities during the period was SEK -4,624k (
-5,767k).

  · Cash and cash equivalents including short-term investments amounted to SEK
9,240k (16,829k) at the end of the period.

  · Genovis launched a follow-up FabRICATOR® that is marketed under the name
FabRICATOR®Z for customers primarily in the pharmaceutical industry for
preclinical research.

  · Genovis presented data from the mAbCHECK project. The system is based on
Genovis’ enzymes combined with Capsenze’s unique technology and Bruker’s cutting
-edge expertise in mass spectrometry.

January - June

  · Net sales rose by about 42% to SEK 6,412k (4,514k).

  · Loss after financial items was SEK 10,292k (loss: 8,642k).

  · Comprehensive income was a loss of SEK 10,355k (loss: 8,642k).

  · Comprehensive income per share basic and diluted totaled SEK -0.45 (-0.41).

  · Cash flow from operating activities during the six-month period was SEK
-9,478k (-11,980k).
Comments from CEO Fredrik Olsson

We are extremely pleased to be able to present the best quarterly sales figures
in the history of the Company. Sales surged 39 percent compared with the same
period last year and 22 percent against the previous quarter. In the first half
of 2015 sales climbed 42 percent compared with last year, which means that after
the first six months we reached nearly 80 percent of total sales for 2014. Sales
increased significantly in both the US market (42 percent) and the European
market (37 percent) compared with last year. Gross profit for the second quarter
improved significantly compared with the corresponding period last year.
However, legal expenses attributable to the judicial process in the US still had
a negative impact, which we expect will diminish over time.

As a result of our successful strategy to transition to direct sales, customers
have quickly accepted new products and placed orders. Our customer base is
steadily growing, which allows more interaction with our customers. Contact with
the end customer is crucial in order to rapidly identify market trends and
needs. Direct sales strengthen our future product development and sales, which
is an important tool to be able to compete in the US and European markets.

Now that we face clear competition in the US, prompt delivery and good customer
service are crucial. Sales growth in the first six months strengthens our
conviction that Genovis is on the on the right track. In particular, it shows
that we can hold our own in a globally competitive market. With our subsidiary
Genovis Inc. and warehouse in the US, we can now provide next-day delivery
throughout North America.

We can conclude that the new products GingisKHAN and FabRICATOR® Z, which were
launched in mid-March and May, respectively, are already responsible for more
than 10 percent of total sales since they were introduced. This shows that
Genovis can develop new products that customers need. It is extremely gratifying
that during the first six months we have shown that we can compete with the
largest companies in both the US and Europe. We will continue to introduce new
products in the autumn to further strengthen the product portfolio and expect
continued positive sales growth.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.
SIX-MONTH REPORT JANUARY – JUNE 2015

Attachments
